Robert J. Kelley - 02 Oct 2021 Form 4 Insider Report for Talis Biomedical Corp

Role
Chief Commercial Officer
Signature
/s/ Karen E. Flick, Attorney-in-Fact for Robert J. Kelley
Issuer symbol
TLIS on OTC
Transactions as of
02 Oct 2021
Net transactions value
$0
Form type
4
Filing time
05 Oct 2021, 16:48:34 UTC
Next filing
09 Dec 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TLIS Stock Option (right to buy) Award +130,000 +44% 427,202 02 Oct 2021 Common Stock 130,000 $6.17 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option shall vest on the first annual anniversary of the vesting commencement date and 1/48th of the shares underlying this option shall vest monthly thereafter over 36 months.
F2 Price not required on initial report of stock option granted.